Page 344 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 344
Chapter 14
To improve efficacy of cancer therapy, fluoropyrimidines are combined with several other anticancer drugs, yet they remain the backbone of therapy for a substantial number of tumour types. Ample research on fluoropyrimidines and DPD (deficiency) has been executed. Right now, prospective DPYD genotyping should be executed for all patients starting treatment with fluoropyrimidines. Additional research will be executed to continue the search for other factors which could predict the onset of severe fluoropyrimidine-induced toxicity.
342
